Outcome of childhood acute lymphoblastic leukemia with induction failure treated by the Japan Association of Childhood Leukemia Study (JACLS) ALL F-protocol

Pediatric Blood and Cancer

Volumn 54, Issue 1, 2010, Pages 71-78

  Suzuki, Nobuhiro ^a   Yumura Yagi, Keiko ^b   Yoshida, Makoto ^c   Hara, Junichi ^d   Nishimura, Shinichiro ^e   Kudoh, Tooru ^f   Tawa, Akio ^g   Usami, Ikuya ^h   Tanizawa, Akihiko ⁱ   Hori, Hiroki ^j   Ito, Yasuhiko ^k   Miyaji, Ryosuke ^l   Oda, Megumi ^m   Kato, Koji ⁿ   Hamamoto, Kazuko ^o   Osugi, Yuko ^d   Hashii, Yoshiko ^p   Nakahata, Tatsutoshi ^q   Horibe, Keizo ^r  

^a SAPPORO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^b OSAKA GENERAL MEDICAL CENTER   (Japan)

^c ASAHIKAWA MEDICAL COLLEGE   (Japan)

^d OSAKA CITY GENERAL HOSPITAL   (Japan)

^e HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^f HOKKAIDO MEDICAL CENTER   (Japan)

^g OSAKA NATIONAL HOSPITAL   (Japan)

^h KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

ⁱ UNIVERSITY OF FUKUI   (Japan)

^j MIE UNIVERSITY HOSPITAL   (Japan)

^k NAGOYA CITY UNIVERSITY HOSPITAL   (Japan)

^l School of Medicine   (Japan)

^m OKAYAMA UNIVERSITY HOSPITAL   (Japan)

ⁿ JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^o ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^p OSAKA UNIVERSITY HOSPITAL   (Japan)

^q KYOTO UNIVERSITY HOSPITAL   (Japan)

^r NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

more..

Author keywords

Acute lymphoblastic leukemia; Chemotherapy; Childhood; Hematopoietic cell transplantation; Induction failure

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; HYDROCORTISONE; METHOTREXATE; MITOXANTRONE; PIRARUBICIN; PREDNISOLONE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONSTIPATION; DIARRHEA; DRUG TREATMENT FAILURE; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; LUNG HEMORRHAGE; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREATITIS; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SCHOOL CHILD; STOMATITIS; TREATMENT OUTCOME; VOMITING; BONE MARROW TRANSPLANTATION; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHILADELPHIA 1 CHROMOSOME; REMISSION; SURVIVAL RATE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; PHILADELPHIA CHROMOSOME; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 73349127050     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22217     Document Type: Article

References (40)

1. Conter V, Arico M, Valsecchi MG, et al. Long-term results of the Italian association of pediatric hematology and oncology (AIEOP) acute lymphoblastic leukemia studies, 1982-1995. Leukemia 2000;14:2196-2204.
2. Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: Results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 2004;104:2690-2696.
3. Pui CH, Relling MV, Sandlund JT, et al. Rationale and design of total therapy study XV for newly diagnosed childhood acute lymphoblastic leukemia. Ann Hematol 2004;83:S124-S126.
4. Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007;109:896-904.
5. Schultz KR, Pullen DJ, Sather HN, et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: A combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood 2007;109:926-935.
6. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 2000;95:3310-3322.
7. Harms DO, Gobel U, Spaar HJ, et al. Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: Results of the randomized trial COALL-92. Blood 2003;102:2736-2740.
8. Kamps WA, Bokkerink JP, Hakvoort-Cammel FG, et al. BFMoriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: Results of DCLSG protocol ALL-8 (1991-1996). Leukemia 2002;16:1099-1111.
9. Vilmer E, Suciu S, Ferster A, et al. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: A CLCG-EORTC report. Children Leukemia Cooperative Group. Leukemia 2000;14:2257-2266.
10. Hill FG, Richards S, Gibson B, et al. Successful treatment without cranial radiotherapy of children receiving intensified chemotherapy for acute lymphoblastic leukaemia: Results of the riskstratified randomized central nervous system treatment trial MRC UKALL XI (ISRC TN 16757172). Br J Haematol 2004;124:33-46.
11. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354:166-178.
12. Ogden AK, Pollock BH, Bernstein ML, et al. Intermediate-dose methotrexate and intravenous 6-mercaptopurine chemotherapy for children with acute lymphoblastic leukemia who did not respond to initial induction therapy. J Pediatr Hematol Oncol 2002;24:182-187.
13. Ochs J, Rivera GK, Pollock BH, et al. Teniposide (VM-26) and continuous infusion cytosine arabinoside for initial induction failure in childhood acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study. Cancer 1990;66:1671-1677.
14. Silverman LB, Gelber RD, Young ML, et al. Induction failure in acute lymphoblastic leukemia of childhood. Cancer 1999;85:1395-1404.
15. Arico M,Valsecchi MG, ConterV, et al. Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II. Blood 2002;100:420-426.
16. Balduzzi A, Valsecchi MG, Uderzo C, et al. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: Comparison by genetic randomisation in an international prospective study. Lancet 2005;366:635-642.
17. Giona F, Testi AM, Rondelli R, et al. ALL R-87 protocol in the treatment of children with acute lymphoblastic leukaemia in early bone marrow relapse. Br J Haematol 1997;99:671-677.
18. Yumura-Yagi K, Hara J, Kurahashi K, et al. Clinical significance of CD7-positive stem cell leukemia: A distinct subtype of mixed lineage leukemia. Cancer 1991;68:2273-2280.
19. Archimbaud E, Leblond V, Michallet M, et al. Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia. Blood 1991;77:1894-1900.
20. Brisco MJ, Sykes PJ, Dolman G, et al. Early resistance to therapy during induction in childhood acute lymphoblastic leukemia. Cancer Res 2000;60:5092-5096.
21. Hongo T, Okada S, Inoue N, et al. Two groups of Philadelphia chromosome-positive childhood acute lymphoblastic leukemia classified by pretreatment multidrug sensitivity or resistance in in vitro testing. Int J Hematol 2002;76:251-259.
22. Schwartz CL, Thompson EB, Gelber RD, et al. Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia. J Clin Oncol 2001;19:1040-1046.
23. Hara J, Park YD,Yoshioka A, et al. Intensification of chemotherapy using block therapies as consolidation and reinduction therapies for acute lymphoblastic leukemia during childhood. Int J Hematol 2001;74:165-172.
24. Berg SL, Blaney SM, Devidas M, et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies:Areport from the Children's Oncology Group. J Clin Oncol 2005;23:3376-3382.
25. Jeha S, Gaynon PS, Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 2006;24:1917-1923.
26. Oudot C, AuclercMF,LevyV, et al. Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: The FRALLE 93 study. J Clin Oncol 2008;26:1496-1503.
27. Rivera GK, Zhou Y, Hancock ML, et al. Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. Cancer 2005;103:368-376.
28. Einsiedel HG, von Stackelberg A, Hartmann R, et al. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: Results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group 87. J Clin Oncol 2005;23:7942-7950.
29. Hunault M, Harousseau JL, Delain M, et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: A GOELAMS trial. Blood 2004;104:3028-3037.
30. Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: Analysis of the LALA-94 trial. J Clin Oncol 2004;22:4075-4086.
31. Eapen M, Raetz E, Zhang MJ, et al. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: A collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood 2006;107:4961-4967.
32. Knechtli CJ, Goulden NJ, Hancock JP, et al. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood 1998;92:4072-4079.
33. van der Velden VH, Joosten SA, Willemse MJ, et al. Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia. Leukemia 2001;15:1485-1487.
34. Bader P, Hancock J, Kreyenberg H, et al. Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia 2002;16:1668-1672.
35. Goulden N, Bader P, Van Der Velden V, et al. Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia. Br J Haematol 2003;122:24-29.
36. Uckun FM,Kersey JH, Haake R, et al. Pretransplantation burden of leukemic progenitor cells as a predictor of relapse after bone marrowtransplantation for acute lymphoblastic leukemia.NEngl J Med 1993;329:1296-1301.
37. Horstmann MA, Hassenpflug WA, zur Stadt U. et al. Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children. Haematologica 2005;90:1701-1703.
38. Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004;351:2276-2285.
39. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004;351:2265-2275.
40. Al-Kasim FA, Thornley I, Rolland M, et al. Single-centre experience with allogeneic bone marrow transplantation for acute lymphoblastic leukaemia in childhood: Similar survival after matched-related and matched-unrelated donor transplants. Br J Haematol 2002;116:483-490.